What is claimed is:

1. An alcohol-resistant controlled release oral pharmaceutical composition of lorazepam, comprising

a sustained release drug-containing core comprising lorazepam in a sustained release formulation;

a delayed release drug-containing core comprising a sustained release drug-containing core comprising lorazepam in a sustained release formulation and an enteric coating surrounding the core; and

a coated substrate surrounded by an alcohol-resistant coating, wherein the substrate of the coated substrate is at least one of the sustained release drug-containing core, the delayed release drug-containing core, or a dosage form comprising both of the sustained release drug-containing core and the delayed release drug-containing core,

wherein the amount of lorazepam released from the coated substrate is 75% or less than the amount of lorazepam released from the uncoated substrate, when measured by dissolution testing at 37.0 ± 0.5 °C and 100 rpm for two hours in an acidic ethanolic aqueous solution comprising 40% ethanol and 0.1 N HCl solution in accordance with USP <711>, and

wherein the amount of lorazepam released from the coated substrate is ± 25% or less, ± 20% or less, ± 10% or less, ± 5% or less, or ± 1% or less, as compared to the amount of lorazepam released from a corresponding substrate without the alcohol-resistant coating, when measured by dissolution testing at 37.0 ± 0.5 °C and 100 rpm for two hours in an aqueous 0.1 N HCl solution, in accordance with USP <711>.

2. The composition of claim 1, wherein the alcohol-resistant coating comprises one or more ethanol-insoluble components selected from the group consisting of ethanol-insoluble polymeric polysaccharides, polymeric ethers, polymeric alcohols, polymeric carboxylic acids, polymeric carboxylic acid esters, and polymeric carboxylic acid alcohols.

3. The composition of claim 1, wherein the alcohol-resistant coating comprises one or more ethanol-insoluble components selected from the group consisting of ethanol-insoluble carbomers, polyethylene oxide polymers, xanthan gum, and alginate.

4. The composition of claim 1, wherein the alcohol-resistant coating comprises sodium carboxymethylcellulose or sodium alginate.

5. The composition of claim 1, wherein the alcohol-resistant coating comprises xanthan gum.

6. The composition of any one of claims 1 to 5, wherein the weight:weight ratio of alcohol-resistant coating to substrate of the coated substrate is at least 1:10; from 1:10 to 3:1; from 1:10 to 1:1; or selected from the group consisting of at least 1:10, at least 1.5:10, at least 2:10, at least 2.5:10, at least 3:10, at least 3.5:10, at least 4:10, at least 4.5:10, at least 5:10, at least 5.5:10, at least 6:10, at least 6.5:10, at least 7:10, at least 7.5:10, at least 8:10, at least 8.5:10, at least 9:10, at least 9.5:10, and at least 1:1.

7. The composition of any one of claims 1 to 6, wherein the coated substrate releases less than 50%, less than 40%, less than 25%, less than 10% , or less than 1% by weight of lorazepam in the presence of alcohol as compared to the amount of lorazepam released by a corresponding substrate without the alcohol-resistant coating, when measured by dissolution testing at 37.0 ± 0.5 °C and 100 rpm for two hours in an acidic ethanolic solution comprising 40% ethanol and 0.1 N HCl solution.

8. The composition of any one of claims 1 to 7, wherein each of the cores is a particle, a granule, a pellet, or a beadlet.

9. The composition of any one of claims 1 to 8, wherein the coated substrate is a dosage form that is a tablet or a capsule.

10. The composition of any one of claims 1 to 9, wherein the coated substrate is the sustained release drug-containing core or a combination of the sustained release drug-containing core and the delayed release drug-containing core.

11. The composition of claim 10, wherein the alcohol-resistant coating is interior to the enteric coating.

12. The composition of claim 10, wherein the alcohol-resistant coating is exterior to the enteric coating.

13. The composition of any one of claims 1 to 7, wherein the coated substrate is formulated in a tablet or filled into a capsule shell, and wherein the tablet or capsule shell optionally is surrounded by an alcohol-resistant coating.

14. The composition of any one of claims 1 to 7, wherein the substrate is in the form of a tablet or capsule surrounded by an alcohol-resistant coating.

15. The composition of any one of claims 1 to 14, wherein the coated substrate is contained within a sachet package.

16. The composition of claim 1, comprising:

coated sustained release beadlets comprising (i) beadlets comprising lorazepam in a sustained release formulation surrounded by an alcohol-resistant coating, wherein the alcohol-resistant coating is less soluble in ethanol than in water; and

coated delayed sustained release beadlets comprising (i) beadlets comprising lorazepam in a sustained release formulation, (ii) an enteric coating surrounding the beadlets, and (iii) an alcohol-resistant coating surrounding the beadlets, wherein the alcohol-resistant coating is less soluble in ethanol than in water, and wherein the alcohol-resistant coating may be interior to or exterior to the enteric coating.

17. The composition of claim 1, comprising:

sustained release beadlets comprising lorazepam in a sustained release formulation; and

delayed sustained release beadlets comprising (i) beadlets comprising lorazepam in a sustained release formulation, (ii) an enteric coating surrounding the beadlets, formulated in a capsule or tablet, wherein the capsule or tablet is surrounded by an alcohol-resistant coating, wherein the alcohol-resistant coating is less soluble in ethanol than in water, and wherein the alcohol-resistant coating may be interior to or exterior to the enteric coating.

18, The composition of claim 1, further comprising lorazepam in an immediate release formulation.

19. A method of reducing the risks of concomitant consumption of lorazepam and alcohol, comprising administering the pharmaceutical composition according to any one of the preceding claims to a subject in need thereof.

20. A method of inhibiting alcohol extraction of lorazepam from an oral pharmaceutical composition, comprising preparing an alcohol-resistant oral pharmaceutical composition according to any one of the preceding claims.